X0609 4 2026-04-01 0 0000886163 LIGAND PHARMACEUTICALS INC LGND 0001950232 Reardon Andrew false 555 HERITAGE DRIVE SUITE 200 JUPITER FL 33458 0 1 0 0 CLO & Secretary 1 Common Stock 2026-04-01 4 M 0 5000 52.27 A 46382 D Common Stock 2026-04-01 4 S 0 460 198.8493 D 45922 D Common Stock 2026-04-01 4 S 0 1302 199.7221 D 44620 D Common Stock 2026-04-01 4 S 0 1238 200.9429 D 43382 D Common Stock 2026-04-01 4 S 0 700 201.8971 D 42682 D Common Stock 2026-04-01 4 S 0 963 203.2218 D 41719 D Common Stock 2026-04-01 4 S 0 337 204.5026 D 41382 D Employee Stock Option (right to buy) 52.27 2026-04-01 4 M 0 5000 0 D 2032-08-01 Common Stock 5000 49444 D The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $198.4000 to $199.3500. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $199.4600 to $200.3300. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $200.6000 to $201.5500. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $201.6500 to $202.1900. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $202.9900 to $203.7100. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $204.0100 to $204.8200. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The stock option vests and is exercisable as to 12.5% of the underlying shares on February 1, 2023, and in 42 substantially equal monthly installments thereafter. /s/Andrew Reardon 2026-04-02